MS/Neuroimmunology
Clinical Research
If you think you may qualify for one of these studies, please contact Neurology Research Partners at (303) 724-4644 or NeurologyResearchPartners@CUAnschutz.edu
| COMIRB # | Title (Please click on the title to see approved advertisement) | Principal Investigator | Eligibility and Information | Advertisement |
|---|---|---|---|---|
| 21-3126 | The Evaluation Of Immune Responses To Sars-Cov-2 mRNA Vaccines In Multiple Sclerosis Patients On Ocrelizumab | Amanda Piquet, MD | Clinical Trials | See Advertisement |
| 12-0968 | Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological Disorders | Enrique Alvarez, MD, PhD | Clinical Trials | N/A |
| 18-1633 | Determining the Effectiveness of Early Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS) | Enrique Alvarez, MD, PhD | Clinical Trials | N/A |
| 17-1884 | Risk Factors in Early Multiple Sclerosis (RISE-MS) | John Corboy, MD | Clinical Trials | See Advertisement |
| 19-0393 | Detection and Risk in Early MS (DREAMS) | Teri Schreiner, MD, MPH | N/A | See Advertisement |
| 09-0952 | Rocky Mountain MS Center Tissue Bank | John Corboy, MD | Clinical Trials | N/A |
| 19-1600 | An Observational Study Of Ocrelizumab Treated Patients With Multiple Sclerosis To Determine The Incidence And Mortality Rates Of Breast Cancer And All Malignancies | Amanda Piquet, MD | N/A | See Advertisement |
| 20-1000 | Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS) | Enrique Alvarez, MD, PhD | Clinical Trials | N/A |
| 16-0156 | Natalizumab for Prevention of Post-Partum Relapses in Patients with Multiple Sclerosis | Teri Schreiner, MD, MPH | Clinical Trials | N/A |
| 20-2153 | Evaluating the Feasibility of Pandemic Forward, Telehealth Based Home Based Infusions for Ocrelizumab Users: Measuring Patient Experiences and Safety Outcomes | Tim Vollmer, MD | Clinical Trials | See Advertisement |
| 19-1040 | A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Ocrelizumab Administration in Patients with Multiple Sclerosis | Amanda Piquet, MD | Clinical Trials | N/A |
| 19-2525 | Lipoic Acid for the Treatment of Progressive Multiple Sclerosis | Robert Gross, MD | Clinical Trials | N/A |
| 20-1569 | A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients with Relapsing-Remitting Multiple Sclerosis | Tim Vollmer, MD | Clinical Trials | See Advertisement |
| 20-0705 | A Single-Arm, Prospective, Multicentre, Open-Label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients with Relapsing Multiple Sclerosis Transitioning from Dimethyl Fumarate or Fingolimod Therapy | Enrique Alvarez, MD, PhD | Clinical Trials | N/A |
| 20-0454 | A Phase 1, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study with an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects with Progressive Multiple Sclerosis | Enrique Alvarez, MD, PhD | Clinical Trials | N/A |
| 20-0695 | Low Load Resistance Training Using Blood Flow Restriction for People with Multiple Sclerosis with Marked Mobility Restriction | Mark Manago, DPT, PhD, PT, NCS | Clinical Trials | See Advertisement |
| 18-0179 | Comparative Effectiveness of an Exercise Intervention Delivered via Telerehabilitation and Conventional Mode of Delivery | Jeffrey Hebert, PT, PhD | Clinical Trials | See Advertisement |
| 20-1527 | Proximal Resistance Training to Improve Walking Capacity and Physical Activity in People with Multiple Sclerosis | Mark Manago, DPT, PhD, PT, NCS | Clinical Trials | See Advertisement |